AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantion in non-Hodgkin lymphoma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 4, 2007, Pages 315-318

  Holtan, Shernan G ^a   Porrata, Luis F ^a   Micallef, Ivana N M ^a   Padley, Douglas J ^a   Inwards, David J ^a   Ansell, Stephen A ^a   Johnston, Patrick B ^a   Gastineau, Dennis A ^a   Markovic, Svetomir N ^a  

^a Mayo Clinic   (United States)

Author keywords

Autograft absolute lymphocyte count; Endpoint; Granulocyte colony stimulating factor

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; AUTOGRAFT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; FEMALE; HUMAN; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; NONHODGKIN LYMPHOMA; SINGLE DRUG DOSE;

EID: 33947184359     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.009     Document Type: Article

References (13)

1. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102:2728-2730.
2. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:1095-1102.
3. Chakrabarti S, Takahashi Y, Read EJ, et al. A comparison of apheresis cell content collected from the same donors mobilized with granulocyte colony stimulating factor (G-CSF) vs. a single injection of AMD3100. Blood 2004; 104:780a (Abstract #2853).
4. Devine SM, Bonde J, Hess DA, et al. A pilot study evaluating the safety and efficacy of AMD3100 for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells in patients with advanced hematologic malignancies. Blood 2004; 104:913a (Abstract #3341).
5. Takahashi Y, Tawad A, Kurlander R, et al. AMD3100 mobilized apheresis product are rich in T-cells that do not undergo a Th-2 type cytokine polarization: implications for allografting. Blood 2005; 106:90a (Abstract #296).
6. Takahashi Y, Chakrabarti S, Sriniivasan R, et al. A detailed phenotypic analysis using six color flow cytometry of lymphocyte subsets mobilized with AMD3100 compared to G-CSE Blood 2004; 104:120a (Abstract #408).
7. Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33:291-298.
8. Porrata LF, Markovic SN. Timely reconstitution of immune competence affects clinical outcome following autologous stem cell transplantation. Clinical Exp Med 2004; 4:78-85.
9. Stiff P, Micallef I, McCarthy P, et al. AMD3100 combined with standard doses of G-CSF leads to rapid, consistent mobilization of hematopoietic progenitor cells in patients with non-Hodgkins lymphoma (NHL) and multiple myeloma. Blood 2004; 104:778a (Abstract #2847).
10. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
11. Franitza S, Grabovsky V, Wald O, et al. Differential usage of VLA-4 and CXCR4 by CD3+CD56+ NKT cells and CD56+CD16+ NK cells regulates their interaction with endothelial cells. Eur J Immunol 2004; 34:1333-1341.
12. Zou L, Barnett B, Safah H, et al. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Research 2004; 64:8451-8455.
13. Fricker SP, Anastassov V, Cox J, et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochemical Pharmacology 2006; 72:588-596.